{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:53:16Z","timestamp":1791078796638,"version":"4.1.0"},"reference-count":60,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T00:00:00Z","timestamp":1312848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold>Worldwide, the hepatitis B virus (HBV) and the hepatitis C virus (HCV) cause, respectively, 600\u2003000 and 350\u2003000 deaths each year. Viral hepatitis is the leading cause of cirrhosis and liver cancer, which in turn ranks as the third cause of cancer death worldwide. Within the WHO European region, approximately 14 million people are chronically infected with HBV, and nine million people are chronically infected with HCV. Lack of reliable epidemiological data on HBV and HCV is one of the biggest hurdles to advancing policy. Risk groups such as migrants and injecting drug users (IDU) tend to be under\u2010represented in existing prevalence studies; thus, targeted surveillance is urgently needed to correctly estimate the burden of HBV and HCV. The most effective means of prevention against HBV is vaccination, and most European Union (EU) countries have universal vaccination programmes. For both HBV and HCV, screening of individuals who present a high risk of contracting the virus is critical given the asymptomatic, and thereby silent, nature of disease. Screening of migrants and IDUs has been shown to be effective and potentially cost\u2010effective. There have been significant advances in the treatment of HCV and HBV in recent years, but health care professionals remain poorly aware of treatment options. Greater professional training is needed on the management of hepatitis including the treatment of liver cancer to encourage adherence to guidelines and offer patients the best possible outcomes. Viral hepatitis knows no borders. EU Member States, guided by the EU, need to work in a concerted manner to implement lasting, effective policies and programmes and make tackling viral hepatitis a public health priority.<\/jats:p>","DOI":"10.1111\/j.1365-2893.2011.01499.x","type":"journal-article","created":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T08:33:42Z","timestamp":1312878822000},"page":"1-16","source":"Crossref","is-referenced-by-count":185,"title":["The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*"],"prefix":"10.1111","volume":"18","author":[{"given":"A.","family":"Hatzakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bruix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Carballo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cavaleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Delarocque\u2010Astagneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Dusheiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Esmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S. F.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Marcellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Papatheodoridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Peterle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Prati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Piorkowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rizzetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Roudot\u2010Thoraval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. C.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Thursz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Valla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. K.","family":"Veldhuijzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wiessing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. R.","family":"Zanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. L. A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,8,9]]},"reference":[{"key":"e_1_2_17_2_2","first-page":"9","article-title":"The global burden of disease of viral hepatitis","volume":"19","author":"Wiersma S","year":"2011","journal-title":"Viral Hepat"},{"key":"e_1_2_17_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02322.x"},{"key":"e_1_2_17_4_2","unstructured":"WHO.Hepatitis B fact sheet no. 204 2009. Available at:http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/. (Accessed on 12 July 2011)."},{"key":"e_1_2_17_5_2","unstructured":"European Liver Patients Association (ELPA).Report on hepatitis patient self\u2010help in Europe. Available at:http:\/\/www.hepsummit2010.org(Accessed on 11 July 2011)."},{"key":"e_1_2_17_6_2","volume-title":"Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C","author":"Institute of Medicine","year":"2010"},{"key":"e_1_2_17_7_2","unstructured":"European Centre for Disease Prevention and Control (ECDC).Surveillance and prevention of hepatitis B and C in Europe. ECDC technical report Stockholm October 2010."},{"key":"e_1_2_17_8_2","unstructured":"European Centre for Disease Prevention and Control (ECDC).Hepatitis B and C in the EU neighbourhood: prevalence burden of disease and screening policies. ECDC technical report Stockholm September 2010."},{"key":"e_1_2_17_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.11.011"},{"key":"e_1_2_17_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.09.014"},{"key":"e_1_2_17_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.016"},{"key":"e_1_2_17_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.1.65"},{"key":"e_1_2_17_13_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff LB","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_17_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.069"},{"key":"e_1_2_17_15_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268810001421"},{"key":"e_1_2_17_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.04.016"},{"key":"e_1_2_17_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22312"},{"key":"e_1_2_17_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14964-1"},{"key":"e_1_2_17_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.1.131"},{"key":"e_1_2_17_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21176"},{"key":"e_1_2_17_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp288"},{"key":"e_1_2_17_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.09.056"},{"key":"e_1_2_17_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000138433.61870.82"},{"key":"e_1_2_17_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000335762.42177.07"},{"key":"e_1_2_17_25_2","unstructured":"World Health Organization global advisory committee on vaccine safety: Response to the paper by MA Hernan and others in Neurology 14th September 2004 issue entitled \u201cRecombinant hepatitis B vaccine and the risk of multiple sclerosis\u201d. Available at:http:\/\/www.who.int\/vaccine_safety\/topics\/hepatitisb\/multiple_sclerosis\/sep_04\/en\/(Accessed 11 July 2011)."},{"key":"e_1_2_17_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67568-X"},{"key":"e_1_2_17_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(96)00062-X"},{"key":"e_1_2_17_28_2","first-page":"1","article-title":"Hepatitis B vaccine: do we need boosters?","volume":"10","author":"Banatvala JE","year":"2003","journal-title":"J Hepatol"},{"key":"e_1_2_17_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)07239-6"},{"key":"e_1_2_17_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67544-7"},{"key":"e_1_2_17_31_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-7-200710020-00004"},{"key":"e_1_2_17_32_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.10.039"},{"key":"e_1_2_17_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckp001"},{"issue":"19","key":"e_1_2_17_34_2","first-page":"1","article-title":"Identification and management of persons with chronic viral hepatitis in Europe, Budapest, March 2010","volume":"1","author":"Viral hepatitis prevention Board","year":"2011","journal-title":"Viral Hepat"},{"key":"e_1_2_17_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17701-0"},{"key":"e_1_2_17_36_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.08.045"},{"key":"e_1_2_17_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23327"},{"key":"e_1_2_17_38_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-10-200711200-00003"},{"key":"e_1_2_17_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.04.013"},{"key":"e_1_2_17_40_2","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver.EASL clinical practice guidelines: management of hepatitis C virus infection.J Hepatol2011;55:245\u201364.","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"e_1_2_17_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.10.001"},{"key":"e_1_2_17_42_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.12.056"},{"key":"e_1_2_17_43_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-6-200809160-00006"},{"key":"e_1_2_17_44_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247133"},{"key":"e_1_2_17_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24199"},{"key":"e_1_2_17_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00130-1"},{"key":"e_1_2_17_47_2","unstructured":"CarballoM CodyR O\u2019ReillyE.International centre for migration health and development. Migration hepatitis B and C September2010. Available at:http:\/\/www.hepsummit2010.org."},{"key":"e_1_2_17_48_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-922067"},{"key":"e_1_2_17_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-9276-8-24"},{"key":"e_1_2_17_50_2","unstructured":"CarballoM.The process of social insertion of migrants refugees and asylum seekers in the context of access to and use of health and social services. Synthesis and recommendations. ICMH\/Synthese Geneva report 2004."},{"issue":"21","key":"e_1_2_17_51_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/ese.13.21.18884-en","article-title":"European monitoring of notifications of hepatitis C virus infection in the general population and among injecting drug users (IDUs) \u2013 the need to improve quality and comparability","volume":"13","author":"Wiessing L","year":"2008","journal-title":"Eurosurveillance"},{"key":"e_1_2_17_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/jurban\/79.4.579"},{"issue":"48","key":"e_1_2_17_53_2","doi-asserted-by":"crossref","DOI":"10.2807\/ese.15.48.19735-en","article-title":"EMCDDA publishes guidelines on testing for HIV, viral hepatitis and other infections in injecting drug users","volume":"15","author":"Wiessing L","year":"2010","journal-title":"Euro Surveill"},{"key":"e_1_2_17_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.08.029"},{"key":"e_1_2_17_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60936-1"},{"key":"e_1_2_17_56_2","doi-asserted-by":"publisher","DOI":"10.1086\/600304"},{"key":"e_1_2_17_57_2","doi-asserted-by":"publisher","DOI":"10.1086\/427449"},{"key":"e_1_2_17_58_2","unstructured":"EMA.Guideline: clinical evaluation of medicinal products intended for treatment of hepatitis B 2006. adopted February 2006."},{"key":"e_1_2_17_59_2","unstructured":"EMA.Guideline: clinical evaluation of direct acting antiviral agents intended for treatment of chronic hepatitis C 2009. adopted May 2009."},{"key":"e_1_2_17_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01196.x"},{"key":"e_1_2_17_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.04.021"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2893.2011.01499.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2893.2011.01499.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T11:54:46Z","timestamp":1741434886000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2893.2011.01499.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,9]]},"references-count":60,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1111\/j.1365-2893.2011.01499.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2893.2011.01499.x","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,9]]}}}